Developer docs
API playgroundTry for free, no card

Search company profiles

Altis Labs

Full company profile

uuid0000v3x

Namestring
Altis Labs
Legal namestring
Altis Labs, Inc.
Websiteurl
altislabs.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial imaging, AI prognostic biomarkers, medical imaging analytics, biopharma AI platform, oncology imaging AI
Industry3 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-Powered Clinical Trial Imaging Analytics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharma Software Licensing
TypeSubscription Recurring
Description

B2B SaaS model providing biopharma sponsors access to AI models via the Nota platform for analyzing clinical trial imaging data. Revenue likely generated through platform licensing and analysis fees per trial or per patient.

altislabs.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Nota
Description

AI-powered imaging biomarker platform that enables biopharma sponsors to manage and automatically analyze imaging data from clinical trials using prognostic AI models. Nota hosts proprietary prognostic models including IPRO for automated patient outcome predictions.

altislabs.com
+2 more records
Core offering1 text field

Altis Labs develops AI-powered imaging analysis software for biopharma clinical trials. Its Nota platform processes CT scans through deep learning models (IPRO) to predict patient outcomes, quantify treatment effects earlier than traditional RECIST measurements, and generate external control arms via Real-World Digital Twins. The platform serves top biopharma sponsors conducting oncology trials, providing patient stratification, treatment effect quantification, and regulatory-grade endpoint analysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • IPRO-Δ had greater association with OS (HR=1.72, 95% CI: 1.38-2.15) than ΔSLD (HR=1.14) in Bayer's Phase 3 NExUS trial
+2 more records
Product overview1 text field

Altis Labs offers the Nota platform, a cloud-based AI-powered imaging biomarker platform that hosts proprietary deep learning models for clinical trial imaging analysis. The core product is IPRO (Imaging-based Prognostication), which includes IPRO-α for baseline predictions and IPRO-Δ for longitudinal change assessment. IPRO processes CT scans through 3D convolutional neural networks to generate prognostic scores and 5,000+ Spatial Imaging Biomarkers per scan. The platform also includes Real-World Digital Twins and External Control Arm products that leverage multimodal real-world data to create AI-matched control groups for clinical trials. Biopharma sponsors use Nota to analyze imaging data from Phase 1-4 clinical trials to more accurately stratify patients and quantify treatment effect earlier in development.

Product and service4 records
1Nota Platform
CategoryAI Imaging Biomarker Platform
Description

Web-based platform for managing and automatically analyzing clinical trial imaging data with AI models. Nota enables users to upload de-identified DICOM data, automatically quality control and index meta- and pixel data, generate IPRO scores and Spatial Imaging Biomarkers, and query data in a secure, access-controlled environment. Designed for biopharma sponsors and clinical research institutions conducting oncology trials.

2IPRO (Imaging-based Prognostication)
CategoryAI Imaging Biomarker
Description

Fully-automated deep learning system that predicts patient outcomes from CT scans. IPRO uses 3D convolutional neural networks trained on longitudinal real-world imaging data to generate prognostic scores and thousands of explainable Spatial Imaging Biomarkers (SIBs) per scan, enabling patient stratification and treatment effect quantification beyond traditional tumor measurements. Serves biopharma sponsors conducting oncology clinical trials.

3Real-World Digital Twins (rwDTs)
CategoryExternal Control Arm Solution
Description

AI-matched digital twins generated from real-world patient data to create External Control Arms (ECAs) for clinical trials. Identifies matching historical patients using baseline imaging characteristics and clinical data to emulate control arm outcomes and treatment effects. Designed for biopharma sponsors running single-arm oncology trials.

4External Control Arm (ECA)
CategoryClinical Trial Design Solution
Description

Product offering enabling biopharma sponsors to generate multimodal external controls using clinical trial imaging data and Altis' real-world imaging data with associated survival outcomes. Used for benchmarking efficacy signal in single-arm trials, augmenting control arms in RCTs, and informing reimbursement strategy.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

Collaboration agreement to leverage AI models for supporting clinical trials, evaluating novel outcome measures to potentially accelerate trial timelines and reduce costs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-28
Description

Multi-year partnership focused on lung, breast, colorectal, prostate, and liver cancer. Combines AI research with UHN's clinical expertise to accelerate cancer research.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-03-12
Description

Research collaboration to develop and evaluate prognostic AI models for breast cancer. Led by Dr. Jeremy Petch at CREATE center.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-23
Description

Early access to AI-driven digital twins for four clinical trials. AstraZeneca independently evaluated IPRO in MYSTIC Phase 3 trial, demonstrating IPRO-Δ enhances survival prediction compared to RECIST.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-23
Description

Early access to AI models via Nota for four clinical trials. Bayer evaluated IPRO in NExUS Phase 3 trial, demonstrating superior prognostic association compared to SLD.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-08-23
Description

Part of international coalition for digital twins in clinical trials. Dr. Benjamin Fine leads initiative via AI Deployment and Evaluation Lab.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-08-23
Description

Academic partner in digital twins initiative. Dr. Omar Khan leads project, presenting results at ELCC 2025 and ESMO.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-24
Description

Coalition member in pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-24
Description

Coalition member in pan-Canadian initiative. Host of INOVAIT network headquarters.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2023-01-24
Description

Canadian data company providing NLP tools for digital twins initiative to facilitate data processing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Imaging AI and imaging CRO focused on oncology clinical trials, offering imaging biomarkers, lesion management, and AI-driven analysis to biopharma sponsors. Directly comparable as an imaging AI vendor serving top pharma in oncology trials.

TypeDirect peer
Description

AI-based multimodal prognostic and predictive biomarker company, notably in prostate cancer, building evidence-based diagnostic tests that help biopharma stratify patients and improve trial outcomes. Closely analogous as an AI prognostic biomarker company targeting biopharma.

TypeDirect peer
Description

AI-enabled real-world evidence and clinical trial solutions company in oncology, providing biopharma with data, analytics, and external control arms. Comparable in addressing trial design, ECA, and oncology-focused RWE for top sponsors.

TypeBroad incumbent
Description

Real-world oncology data and analytics platform acquired by Roche for $1.9B; provides RWE, EHR-derived datasets, and clinical research tools to biopharma. Adjacent incumbent in AI/real-world data for oncology trials.

5Tempus
TypeBroad incumbent
Description

AI-enabled precision medicine company with multimodal data (imaging, molecular, clinical) and biopharma services spanning trial design, biomarker discovery, and CDx. Comparable as a large multimodal AI/data platform for biopharma R&D.

TypeDirect peer
Description

AI-for-drug-discovery and clinical research company that builds predictive models on multimodal patient data to support biopharma trial design and target identification. Comparable as a biopharma-focused AI platform leveraging real-world data.

TypeDirect peer
Description

AI pathology company developing clinical-grade diagnostic and biomarker products for oncology, with biopharma partnerships around trial endpoints and CDx. Comparable as an AI-driven diagnostic/biomarker company serving oncology drug development.

TypeDirect peer
Description

AI-powered pathology platform offering biomarker discovery, diagnostics, and biopharma research partnerships, including partnerships with pharma on clinical trial endpoints. Comparable as a pathology/imaging AI vendor for oncology trials.

TypeBroad incumbent
Description

Market-leading clinical trial technology platform offering EDC, eCOA, imaging, and AI-driven analytics to biopharma. Comparable incumbent in clinical trial imaging/analytics, representing both a potential channel and competitor.

TypeBroad incumbent
Description

Life sciences and clinical research technology platform from Alphabet, providing real-world data, decentralized trials, and biomarker solutions to biopharma. Comparable as a well-capitalized technology provider in clinical research and precision health.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Altis Labs

AI-Powered Clinical Trial Imaging Analyticsaltislabs.com

Altis Labs firmographics

Firmographics
Name
Altis Labs
Legal name
Altis Labs, Inc.
Website
https://altislabs.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Altis Labs industry classification

Industry
Product category
AI-Powered Clinical Trial Imaging Analytics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Clinical trial imaging
  • AI prognostic biomarkers
  • Medical imaging analytics
  • Biopharma AI platform
  • Oncology imaging AI

Where Altis Labs is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Altis Labs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Biopharma Software Licensing: B2B SaaS model providing biopharma sponsors access to AI models via the Nota platform for analyzing clinical trial imaging data. Revenue likely generated through platform licensing and analysis fees per trial or per patient.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Altis Labs product offering

Product offering

Core offering

Altis Labs develops AI-powered imaging analysis software for biopharma clinical trials. Its Nota platform processes CT scans through deep learning models (IPRO) to predict patient outcomes, quantify treatment effects earlier than traditional RECIST measurements, and generate external control arms via Real-World Digital Twins. The platform serves top biopharma sponsors conducting oncology trials, providing patient stratification, treatment effect quantification, and regulatory-grade endpoint analysis.

Product overview

Altis Labs offers the Nota platform, a cloud-based AI-powered imaging biomarker platform that hosts proprietary deep learning models for clinical trial imaging analysis. The core product is IPRO (Imaging-based Prognostication), which includes IPRO-α for baseline predictions and IPRO-Δ for longitudinal change assessment. IPRO processes CT scans through 3D convolutional neural networks to generate prognostic scores and 5,000+ Spatial Imaging Biomarkers per scan. The platform also includes Real-World Digital Twins and External Control Arm products that leverage multimodal real-world data to create AI-matched control groups for clinical trials. Biopharma sponsors use Nota to analyze imaging data from Phase 1-4 clinical trials to more accurately stratify patients and quantify treatment effect earlier in development.

Differentiator

Problem solved

Functional benefit

Brands

  • Nota: AI-powered imaging biomarker platform that enables biopharma sponsors to manage and automatically analyze imaging data from clinical trials using prognostic AI models. Nota hosts proprietary prognostic models including IPRO for automated patient outcome predictions.
  • IPRO
  • Real-World Digital Twins (rwDTs)

Products and services

  • Nota Platform Web-based platform for managing and automatically analyzing clinical trial imaging data with AI models. Nota enables users to upload de-identified DICOM data, automatically quality control and index meta- and pixel data, generate IPRO scores and Spatial Imaging Biomarkers, and query data in a secure, access-controlled environment. Designed for biopharma sponsors and clinical research institutions conducting oncology trials.
  • IPRO (Imaging-based Prognostication) Fully-automated deep learning system that predicts patient outcomes from CT scans. IPRO uses 3D convolutional neural networks trained on longitudinal real-world imaging data to generate prognostic scores and thousands of explainable Spatial Imaging Biomarkers (SIBs) per scan, enabling patient stratification and treatment effect quantification beyond traditional tumor measurements. Serves biopharma sponsors conducting oncology clinical trials.
  • Real-World Digital Twins (rwDTs) AI-matched digital twins generated from real-world patient data to create External Control Arms (ECAs) for clinical trials. Identifies matching historical patients using baseline imaging characteristics and clinical data to emulate control arm outcomes and treatment effects. Designed for biopharma sponsors running single-arm oncology trials.
  • External Control Arm (ECA) Product offering enabling biopharma sponsors to generate multimodal external controls using clinical trial imaging data and Altis' real-world imaging data with associated survival outcomes. Used for benchmarking efficacy signal in single-arm trials, augmenting control arms in RCTs, and informing reimbursement strategy.

Quantifiable outcome

  • IPRO-Δ had greater association with OS (HR=1.72, 95% CI: 1.38-2.15) than ΔSLD (HR=1.14) in Bayer's Phase 3 NExUS trial
  • +2 more outcomes

Companies that use Altis Labs

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Altis Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Altis Labs partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and supporting.

  • Johnson & Johnson Innovative MedicinecoreStrategic or Co-development Partner · 23 June 2025Collaboration agreement to leverage AI models for supporting clinical trials, evaluating novel outcome measures to potentially accelerate trial timelines and reduce costs.
  • University Health Network (UHN)coreStrategic or Co-development Partner · 28 May 2025Multi-year partnership focused on lung, breast, colorectal, prostate, and liver cancer. Combines AI research with UHN's clinical expertise to accelerate cancer research.
  • Hamilton Health SciencesmajorStrategic or Co-development Partner · 12 March 2025Research collaboration to develop and evaluate prognostic AI models for breast cancer. Led by Dr. Jeremy Petch at CREATE center.
  • AstraZenecacoreStrategic or Co-development Partner · 23 August 2023Early access to AI-driven digital twins for four clinical trials. AstraZeneca independently evaluated IPRO in MYSTIC Phase 3 trial, demonstrating IPRO-Δ enhances survival prediction compared to RECIST.
  • Bayer PharmaceuticalscoreStrategic or Co-development Partner · 23 August 2023Early access to AI models via Nota for four clinical trials. Bayer evaluated IPRO in NExUS Phase 3 trial, demonstrating superior prognostic association compared to SLD.
  • Trillium Health PartnersmajorStrategic or Co-development Partner · 23 August 2023Part of international coalition for digital twins in clinical trials. Dr. Benjamin Fine leads initiative via AI Deployment and Evaluation Lab.
  • University of CalgarymajorStrategic or Co-development Partner · 23 August 2023Academic partner in digital twins initiative. Dr. Omar Khan leads project, presenting results at ELCC 2025 and ESMO.
  • BC CancermajorStrategic or Co-development Partner · 24 January 2023Coalition member in pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning.
  • Sunnybrook Research InstitutemajorStrategic or Co-development Partner · 24 January 2023Coalition member in pan-Canadian initiative. Host of INOVAIT network headquarters.
  • SapienSecuresupportingTechnology or Integration · 24 January 2023Canadian data company providing NLP tools for digital twins initiative to facilitate data processing.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Altis Labs competitors and assessment

Company assessment

Direct peers

  • Median Technologies: Imaging AI and imaging CRO focused on oncology clinical trials, offering imaging biomarkers, lesion management, and AI-driven analysis to biopharma sponsors. Directly comparable as an imaging AI vendor serving top pharma in oncology trials.
  • Artera (formerly ArteraAI): AI-based multimodal prognostic and predictive biomarker company, notably in prostate cancer, building evidence-based diagnostic tests that help biopharma stratify patients and improve trial outcomes. Closely analogous as an AI prognostic biomarker company targeting biopharma.
  • ConcertAI: AI-enabled real-world evidence and clinical trial solutions company in oncology, providing biopharma with data, analytics, and external control arms. Comparable in addressing trial design, ECA, and oncology-focused RWE for top sponsors.
  • Owkin: AI-for-drug-discovery and clinical research company that builds predictive models on multimodal patient data to support biopharma trial design and target identification. Comparable as a biopharma-focused AI platform leveraging real-world data.
  • Paige.AI: AI pathology company developing clinical-grade diagnostic and biomarker products for oncology, with biopharma partnerships around trial endpoints and CDx. Comparable as an AI-driven diagnostic/biomarker company serving oncology drug development.
  • PathAI: AI-powered pathology platform offering biomarker discovery, diagnostics, and biopharma research partnerships, including partnerships with pharma on clinical trial endpoints. Comparable as a pathology/imaging AI vendor for oncology trials.

Broad incumbents

  • Flatiron Health: Real-world oncology data and analytics platform acquired by Roche for $1.9B; provides RWE, EHR-derived datasets, and clinical research tools to biopharma. Adjacent incumbent in AI/real-world data for oncology trials.
  • Tempus: AI-enabled precision medicine company with multimodal data (imaging, molecular, clinical) and biopharma services spanning trial design, biomarker discovery, and CDx. Comparable as a large multimodal AI/data platform for biopharma R&D.
  • Medidata (Dassault Systèmes): Market-leading clinical trial technology platform offering EDC, eCOA, imaging, and AI-driven analytics to biopharma. Comparable incumbent in clinical trial imaging/analytics, representing both a potential channel and competitor.
  • Verily (Alphabet): Life sciences and clinical research technology platform from Alphabet, providing real-world data, decentralized trials, and biomarker solutions to biopharma. Comparable as a well-capitalized technology provider in clinical research and precision health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Altis Labs social profiles

Digital presence

Altis Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Altis Labs leadership team

Management profile

Number of profiles

Profiles15 records

Altis Labs funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Altis Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altis Labs

What does Altis Labs do?

Altis Labs develops AI-powered imaging analysis software for biopharma clinical trials. Its Nota platform processes CT scans through deep learning models (IPRO) to predict patient outcomes, quantify treatment effects earlier than traditional RECIST measurements, and generate external control arms via Real-World Digital Twins. The platform serves top biopharma sponsors conducting oncology trials, providing patient stratification, treatment effect quantification, and regulatory-grade endpoint analysis.

Is Altis Labs a public or private company?

Altis Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Altis Labs founded?

Altis Labs was founded in 2019. It employs 11 to 50 people.

Where is Altis Labs based?

Altis Labs is headquartered in Toronto, Canada, in the North America region.

How does Altis Labs make money?

One revenue line is on record: biopharma Software Licensing.

Who are Altis Labs's main competitors?

Direct peers on record are Median Technologies, Artera (formerly ArteraAI), ConcertAI, Owkin, Paige.AI and PathAI. Broad incumbents are Flatiron Health, Tempus, Medidata (Dassault Systèmes) and Verily (Alphabet).

Does Altis Labs have an API?

No public API is recorded for Altis Labs.

What industry is Altis Labs in?

Altis Labs's product category is AI-Powered Clinical Trial Imaging Analytics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BetaKitAltis Labs raises $25 million USD Series A to expand AI for cancer trialsAltis Labs closed a $25 million Series A round to expand its AI-powered prognosis platform for cancer trials. The company's IPRO model detected treatment effects 11 months before primary progression-free survival and 26 months before overall survival in a lung cancer trial. Funding will apply AI to more cancer types and establish AI endpoints as a standard.WebrazziOnkoloji ve klinik araştırmaları için yapay zeka geliştiren Altis Labs, 25 milyon dolar yatırım aldıAltis Labs, a Canadian AI company for oncology and clinical research, raised $25 million in a Series A led by OrbiMed and Qiming Venture Partners USA. The funds will expand AI models across cancer types, scale commercial applications with biopharma firms, and promote AI-driven endpoints in clinical trials. The company's IPRO model analyzes radiology images to predict patient survival.The SaaS NewsAltis Labs Raises $25M Series AAltis Labs, a Toronto-based AI endpoint company, raised $25 million in Series A funding led by OrbiMed and Qiming Venture Partners USA. The capital will expand its AI models across cancer types, scale commercial deployment with biopharmaceutical partners, and establish AI endpoints as a standard for oncology trials.Medical Device NetworkAltis Labs’ AI software detected treatment benefit earlier in oncology trialAltis Labs' AI imaging software detected treatment benefit earlier in a Johnson & Johnson Phase III lung cancer trial than standard endpoints. The IPRO system defined response as a ≥50% improvement in its score, favoring the investigational treatment from week 16, while RECIST-based ORR failed to anticipate overall survival benefit. The data was presented at WCLC 2026 in Seoul.ThelogicToronto-based AI health firm Altis Labs raises US$25MAltis Labs, a Toronto-based AI health firm, raised $25M in a round co-led by OrbiMed and Qiming Venture Partners USA. The company will use the funds to expand its AI models across more cancer types and scale with global biopharmaceutical companies. Its technology analyzes medical scans to help drug companies determine sooner whether an experimental treatment is likely to extend patients' lives.TechjacksolutionsAltis Labs Raises $25M to Scale AI Oncology Trial EndpointsAltis Labs closed a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA. The company will use the funds to expand its AI imaging models across additional cancer types and scale commercial deployment with global biopharmaceutical partners.BioSpaceAltis Labs AI Imaging Endpoint Predicts Overall Survival Benefit in Phase 3 Lung Cancer Trial: Data Presented at IASLC WCLC 2026Altis Labs presented post-hoc analysis of its IPRO AI endpoint in the MARIPOSA Phase 3 trial, showing IPRO Response Rate favored the investigational treatment from Week 16. The ratio was 1.33 (95% CI 1.03-1.71), while RECIST-based ORR failed to anticipate the 12+ month median overall survival benefit.ThebiostartupsAltis Labs Secures $6M in Seed Funding to Drive AI Platform for Clinical TrialsAltis Labs, a computational imaging company, closed a US$6 million seed funding round co-led by Benchstrength and Debiopharm Innovation Fund to develop its AI-powered clinical trial imaging platform, Nota. The platform analyzes medical imaging data from clinical trials to predict clinical endpoints and quantify treatment effects beyond traditional tumor size measurements, with leading biopharma companies including Bayer Pharmaceuticals already using the technology. The funding will scale Nota across solid tumor types and therapeutic areas to help sponsors generate higher quality evidence earlier in clinical development.DigitalsuperclusterUsing AI to Accelerate Drug DevelopmentToronto-based AI company Altis Labs has developed digital twin technology using a dataset of over 182 million real-world cancer images to predict patient outcomes and accelerate oncology drug trials. In 2025, their IPRO model successfully reanalyzed AstraZeneca's failed 2017 MYSTIC lung cancer trial, demonstrating superior predictive accuracy compared to traditional tumor size measurements. The company has partnered with AstraZeneca and Bayer Pharmaceuticals, with their technology currently deployed across four Phase III trials involving nearly 4,000 patients.Altislabsaltislabs.comAltis Labs demonstrated that their AI-powered digital twins could replicate control arm outcomes in AstraZeneca's Phase 3 MYSTIC trial for metastatic non-small cell lung cancer. The findings support the launch of a new product enabling clinical development teams to generate external controls using comprehensive real-world data. These results may help enhance single-arm trials and inform treatment efficacy assessments in oncology.